Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BupARO
- Development stage
- Preclinical
- Lead developer
- SafeRx Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Sublingual, Buccal, Transdermal, Subcutaneous, Intramuscular, Subdermal, Intravenous, Rectal
01
Overview
**BupARO** is a development-stage, matrix-based fixed-dose combination from SafeRx Pharmaceuticals containing buprenorphine hydrochloride, naloxone hydrochloride, and disulfiram. It is part of SafeRx's alcohol-resistant opioid platform and is intended for opioid use disorder and moderate-to-severe pain refractory to non-opioid therapy when enforced alcohol sobriety is desired. Buprenorphine provides partial mu-opioid receptor agonism, naloxone provides opioid-receptor antagonism intended to deter parenteral misuse, and disulfiram inhibits aldehyde dehydrogenase to deter alcohol consumption and reduce the danger of concurrent opioid and alcohol exposure.
- Other names
- BupARObuprenorphine hydrochloride + naloxone hydrochloride + disulfiram
02
Targets
MOR (Mu opioid receptor)ALDH1A1 (Aldehyde dehydrogenase 1 family member A1)
Beyond the preview
Go deeper on BupARO.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BupARO.